BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 22998452)

  • 21. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
    Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
    Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
    Shi FF; Gunn GR; Snyder LA; Goletz TJ
    Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Latest developments in MUC1 immunotherapy.
    Taylor-Papadimitriou J; Burchell JM; Graham R; Beatson R
    Biochem Soc Trans; 2018 Jun; 46(3):659-668. PubMed ID: 29784646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MUC1 antibody-based therapeutics: the promise of cancer immunotherapy.
    Pourjafar M; Samadi P; Saidijam M
    Immunotherapy; 2020 Dec; 12(17):1269-1286. PubMed ID: 33019839
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
    Du JJ; Zou SY; Chen XZ; Xu WB; Wang CW; Zhang L; Tang YK; Zhou SH; Wang J; Yin XG; Gao XF; Liu Z; Guo J
    Chem Asian J; 2019 Jun; 14(12):2116-2121. PubMed ID: 31042017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
    Agrawal B; Gendler SJ; Longenecker BM
    Mol Med Today; 1998 Sep; 4(9):397-403. PubMed ID: 9791863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
    Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
    Front Immunol; 2018; 9():2481. PubMed ID: 30455687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
    Ryan SO; Turner MS; Gariépy J; Finn OJ
    Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
    Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
    Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
    Scholl SM; Balloul JM; Le Goc G; Bizouarne N; Schatz C; Kieny MP; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres B
    J Immunother; 2000; 23(5):570-80. PubMed ID: 11001550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MUC1 and breast cancer.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies used for MUC1 immunotherapy: preclinical studies.
    Tang CK; Apostolopoulos V
    Expert Rev Vaccines; 2008 Sep; 7(7):951-62. PubMed ID: 18767945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
    Beatty PL; Narayanan S; Gariépy J; Ranganathan S; Finn OJ
    Cancer Prev Res (Phila); 2010 Apr; 3(4):438-46. PubMed ID: 20332301
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
    Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
    Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
    Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [MUC1, a therapeutic target in oncology].
    Limacher JM; Acres B
    Bull Cancer; 2007 Mar; 94(3):253-7. PubMed ID: 17371767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TG4010: a vaccine with a therapeutic role in cancer.
    Arriola E; Ottensmeier C
    Immunotherapy; 2016 May; 8(5):511-9. PubMed ID: 27140406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
    Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
    Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.
    Mukherjee P; Tinder TL; Basu GD; Pathangey LB; Chen L; Gendler SJ
    Breast Dis; 2004; 20():53-63. PubMed ID: 15687707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.